Medical Marijuana

One of the most egregious outcomes of marijuana prohibition is that many sick people cannot legally access the medicine that works best for them. The Drug Policy Alliance (DPA) is committed to legalizing marijuana at the state and federal levels and improving medical marijuana programs to better protect patients’ rights and access to medicine.

Current Medical Marijuana Laws in the U.S.

Upcoming Initiatives

Three states will consider initiatives that allow access to cannabis for those with qualifying medical conditions and establish state regulatory systems for the cultivation and distribution of cannabis to qualified patients. Read more about the initiatives:

  • Arkansas
  • Florida
  • North Dakota

Find out about all the initiatives this year.


Take Action

The CARERS Act is the first-ever bill in the U.S. Senate to let states legalize marijuana for medical use. Tell your Senators to legalize medical marijuana nationwide!


Why Should We Legalize?

Provide effective medicine
For many seriously ill people, medical marijuana is the only medicine that relieves their pain and suffering, or treats symptoms of their medical condition, without debilitating side effects.

Marijuana has been shown to alleviate symptoms of a huge variety of serious medical conditions including cancer, AIDS, and glaucoma, and is often an effective alternative to synthetic painkillers.

Advance research
Marijuana prohibition has thwarted research within the United States to uncover the best and most effective uses for marijuana as a medicine. Legalization would allow research into marijuana’s medical benefits to move forward.

Featured Resources

Medical Marijuana
Marijuana Facts
Why Are CBD-Focused Laws Not Enough?
Marijuana Concentrates
The DEA: Four Decades of Impeding and Rejecting Science

New Mexico Department of Health’s Medical Cannabis Medical Advisory Board Unanimously Recommends to Keep PTSD as a Qualifying Condition

The Final Decision Rests in the Hands of the Acting Secretary of Health

(Santa Fe, NM) – Today, the New Mexico’s Medical Cannabis Program’s Medical Advisory Board unanimously recommended to the Acting Secretary of Health to keep PTSD as qualifying condition and to deny Dr. William Ulwelling’s petition to remove PTSD from the list of eligible medical conditions for enrollment in the program. The Secretary of Health will have the final decision.

Contact:  Emily Kaltenbach 505-920-5256

Medical Cannabis Patients, including Montel Williams, Oppose Petition to Withdraw PTSD as a Qualifying Condition in New Mexico

New Mexico Department of Health’s Medical Cannabis Medical Advisory Board Will Hear the Petition, Tomorrow, in Santa Fe

Psychiatrists, Military Veterans and Other Patients Scheduled to Testify at the Hearing, Asking the Governor and the Secretary of Health Not to Take Away Their Medicine

(Santa Fe, NM) – Tomorrow, from 1 to 5 pm, the New Mexico’s Medical Cannabis Program’s Medical Advisory Board will hold a public hearing to consider Dr. William Ulwelling’s petition to remove PTSD from the list of eligible medical conditions for enrollment in the program. The hearing is scheduled in the Harold Runnels Building’s auditorium, 1190 St. Francis Drive in Santa Fe.  The Secretary of Health will have the final decision.

Contact:  Emily Kaltenbach 505-920-5256

Don't Take Away our Medicine!

October 25, 2012

A campaign to protect safe access to medical marijuana for PTSD patients

Patients, Physicians and Advocates Launch Campaign to Protect Patients with PTSD Access to Medical Cannabis

Continued access to medicine is being threatened by a request to withdraw PTSD as a qualifying condition for the New Mexico Medical Cannabis Program

Military veterans and other patients to petition the Governor and the Secretary of Health - Don’t Take Away Our Medicine.

Contact:  Emily Kaltenbach 505-920-5256

Medical Marijuana Advocates Mount Challenge to Schedule I Designation

Tues: U.S. Court of Appeals for the D.C. Circuit Will Hear Oral Arguments

DPA Statement: Feds’ Claim of “No Medical Use” Ignores Science

On Tuesday, October 16, the U.S. Court of Appeals for the District of Columbia Circuit will hear oral arguments in a case challenging the Drug Enforcement Administration’s decision to designate marijuana as a Schedule I substance. Schedule I is the most restrictive category for controlled substances, including those drugs defined as having a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision.

Tony Newman (646) 335-5384 or Tommy McDonald 510-229-5215

Medical Marijuana (English/Spanish)

June 1, 2016

One of the most egregious outcomes of marijuana prohibition is that many seriously ill people cannot legally access the medicine that works best for them. Twenty-four states, the District of Columbia, Guam and Puerto Rico have passed laws legalizing the use of marijuana for qualifying patients under state law. While state medical marijuana programs differ from one another in significant ways, most are tightly controlled programs regulated by the state departments of public health.

Faces of Medical Marijuana

January 31, 2013

For many people, medical marijuana is the only medicine that relieves their pain and suffering, or treats symptoms of their medical condition, without debilitating side effects. Marijuana has been shown to alleviate symptoms of a broad variety of serious medical conditions including cancer, AIDS, multiple sclerosis and glaucoma, and is often an effective alternative to synthetic painkillers. These are the stories of people who have experienced the medical safety and efficacy of marijuana in their own lives.

CA Supreme Court Decision Allows Localities to Implement Regulatory Programs for Medical Marijuana Dispensaries

Court dismisses Pack v. City of Long Beach

Yesterday, the California Supreme Court dismissed the case of Pack v. City of Long Beach.  The Pack case addresses the issue of whether local regulations governing medical marijuana production and distribution are preempted by the federal law Controlled Substances Act.  The Supreme Court decision to dismiss this case means that localities can move forward enacting and implementing regulatory programs as they have been for many years.

Tamar Todd 510-229-5213 or Amanda Reiman 510-730-2811

Page 19 of 26
Syndicate content